Hengrui Pharmaceuticals: Subsidiary receives approval notice for HRS-2129 tablet clinical trial Currently, there are no drugs with the same target approved for marketing in China.

Hengrui Pharmaceuticals announced that its subsidiaries Shandong Shengdi Pharmaceuticals Co., Ltd. and Shanghai Hengrui Pharmaceuticals Co., Ltd. have received the "Drug Clinical Trial Approval Notification" issued by the National Medical Products Administration for HRS-2129 tablets, approving clinical trials for the indications of peripheral neuropathic pain in adult diabetic patients and pain in adult osteoarthritis. HRS-2129 tablets are intended for the treatment of acute and chronic pain, and currently there are no approved drugs with the same target in China. As of now, approximately 112 million RMB has been invested in the research and development of this project. According to relevant laws and regulations, after obtaining the Drug Clinical Trial Approval Notification, clinical trials must still be conducted and approved by the National Medical Products Administration before production and marketing.